Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

Ads

You May Also Like

Mateon Therapeutics to Present at 29th Annual ROTH Conference

SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), ...

Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer

GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics ...